Welcome to our dedicated page for Esperion Therape SEC filings (Ticker: ESPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Esperion Therapeutics filings document the regulatory record of a commercial-stage biopharmaceutical company focused on LDL-C lowering, cardiovascular-risk therapies, and related cardiometabolic programs. Its Form 8-K reports cover operating and financial results, clinical or regulatory disclosures, material agreements, capital-structure matters, and material-event updates tied to its commercial portfolio and development activities.
Esperion's SEC record also includes proxy disclosures on shareholder voting, board governance, executive compensation, equity awards, and pay-versus-performance information. Recent filings describe common stock registered on Nasdaq under ESPR, term-loan and credit-agreement amendments, acquisition-related financing, commercial leadership appointments, and other governance and compensation arrangements.
Esperion Therapeutics, Inc. filed an initial ownership report for a senior executive showing no equity holdings. The filing is a Form 3 for the company’s Chief Commercial Officer, who is classified as an officer of Esperion Therapeutics, Inc. (ticker ESPR). The event date for this ownership status is listed as 11/17/2025. According to the remarks, no securities of Esperion, either direct or derivative, are beneficially owned by this reporting person as of that date.
Esperion Therapeutics (ESPR) reported Q3 2025 results showing stronger top-line momentum but ongoing losses. Total revenue reached $87.3 million, up from $51.6 million a year ago, driven by product sales of $40.7 million (vs. $31.1 million) and collaboration revenue of $46.7 million (vs. $20.5 million). Operating loss narrowed to $10.0 million, but higher interest expense brought net loss to $31.3 million (vs. $29.5 million). Year‑to‑date, revenue was $234.7 million with a net loss of $84.5 million.
Cash and cash equivalents were $92.4 million as of September 30, 2025, with operating cash outflow of $58.3 million year‑to‑date. The balance sheet reflects a royalty sale liability of $294.2 million (interest expense $14.6 million in Q3) and long‑term debt of $151.7 million under a December 2024 credit agreement. Accounts receivable grew to $119.0 million and inventories to $108.5 million, supporting higher sales. The company settled several generic challenges in 2025 and continues defending remaining ANDA cases; certain asserted patents extend into 2040. Shares outstanding were 239,063,437 as of October 31, 2025.
Esperion Therapeutics filed a Form 8-K stating it furnished a press release announcing financial results for the three and nine months ended September 30, 2025.
The information under Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference under the Securities Act except as specifically referenced.
Esperion Therapeutics appointed John B. Harlow, Jr. as Chief Commercial Officer, effective November 17, 2025. The hire adds a veteran commercial leader with prior CCO roles at Melinta Therapeutics and Baudax Bio.
Under his agreement, Harlow will receive a $535,000 base salary, a target bonus equal to 45% of salary, and a $35,000 sign-on bonus. Equity awards include options for 380,000 shares at the grant-date closing price and 424,536 RSUs, each vesting over four years, subject to continued service. Severance provides one year of salary (and, upon a sale event, salary plus target bonus) and COBRA-related cash payments, subject to customary release conditions.
Esperion Therapeutics (ESPR) reported an insider transaction by its General Counsel. On 10/17/2025, the officer sold 1,248 shares of common stock at $2.6245 per share. The filing states the shares were sold to satisfy tax obligations on vested restricted stock units.
Following the sale, the officer directly owned 392,422 shares. This Form 4 reflects a tax-related sale rather than an open-market disposition for investment purposes.
Esperion Therapeutics, Inc. filed an 8-K reporting a material event that centers on a securities offering. The filing references two press releases dated October 7, 2025: one announcing the offering and one announcing the pricing of the offering. The company also disclosed an opinion of Goodwin Procter LLP and the firm's consent (included as Exhibit 5.1). The document includes the interactive data cover page and is signed by Sheldon Koenig, President and Chief Executive Officer on October 8, 2025. The filing shows the offering has been publicly announced and legally documented, but it does not disclose offering size, securities type, or net proceeds.
Esperion Therapeutics, Inc. is offering 30,000,000 shares of common stock at a public offering price of $2.50 per share, with an underwriter option for an additional 4,500,000 shares. Estimated net proceeds are approximately $70.2M (or $80.7M if option exercised). The company plans to use proceeds to fund commercialization of NEXLETOL and NEXLIZET, R&D, working capital and general corporate purposes. Recent corporate developments include a settlement with Dr. Reddy’s that delays generic entry for NEXLETOL and NEXLIZET in the U.S. until April 19, 2040, and regulatory progress with approvals and filings in Japan, Canada, Israel and Australia with expected national pricing/approvals in late 2025 to 2026. The offering will dilute new investors; pro forma net tangible book value remains negative at $(1.56) per share after the offering, producing an immediate dilution of $4.06 per share to new investors.
Esperion Therapeutics, Inc. is offering additional shares of its common stock on a shelf registration, with the final public offering price to be set at pricing. The company reported a closing Nasdaq price of $3.30 per share on October 3, 2025 and had 202,149,464 shares outstanding as of June 30, 2025. The prospectus details intended uses of proceeds for commercialization of NEXLETOL and NEXLIZET, pipeline development, working capital and general corporate purposes. Recent corporate developments include a settlement with Dr. Reddy’s delaying generic entry in the U.S. until April 19, 2040 under specified conditions. The company reported a pro forma net tangible book deficit of approximately $(433.5) million (about $(2.14) per share) as of June 30, 2025, and discloses material dilution and volatility risks for investors.
Esperion Therapeutics, Inc. filed a current report to note that on October 7, 2025 it posted an updated corporate presentation on its investor relations website. The same presentation, dated October 2025, is also provided as Exhibit 99.1 so investors can review the materials directly through the SEC system.
The filing does not introduce new financial statements or disclose specific transaction details. Instead, it formally records that the latest corporate overview and investor slide deck are now publicly available, helping ensure all market participants have equal access to the company’s updated messaging.
Esperion Therapeutics insider transaction: Benjamin Looker, listed as General Counsel and an officer, reported a sale of 6,267 shares of Esperion Therapeutics common stock on 09/17/2025 at a reported price of $2.804 per share. The filing states the shares were sold to satisfy tax obligations on vested restricted stock units. After the sale, Mr. Looker is reported to beneficially own 393,670 shares, held directly. The Form 4 was signed by a power of attorney on 09/18/2025. The report contains no other derivative transactions or additional explanatory disclosures.